{"id":"NCT03398148","sponsor":"AbbVie","briefTitle":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-03-07","primaryCompletion":"2022-11-09","completion":"2023-05-11","firstPosted":"2018-01-12","resultsPosted":"2025-01-16","lastUpdate":"2025-01-16"},"enrollment":1558,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis (UC)"],"interventions":[{"type":"DRUG","name":"risankizumab IV","otherNames":["ABBV-066","BI 655066"]},{"type":"DRUG","name":"placebo for risankizumab","otherNames":[]},{"type":"DRUG","name":"risankizumab SC","otherNames":["ABBV-066","BI 655066"]}],"arms":[{"label":"Substudy 1, Induction Period 1: Double-blind Placebo IV","type":"PLACEBO_COMPARATOR"},{"label":"Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV","type":"EXPERIMENTAL"},{"label":"Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV","type":"EXPERIMENTAL"},{"label":"Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV","type":"EXPERIMENTAL"},{"label":"Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV","type":"EXPERIMENTAL"},{"label":"Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC","type":"EXPERIMENTAL"},{"label":"Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC","type":"EXPERIMENTAL"},{"label":"Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV","type":"EXPERIMENTAL"},{"label":"Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo","type":"EXPERIMENTAL"},{"label":"Substudy 2, Induction Period 1: Double-blind Placebo IV","type":"PLACEBO_COMPARATOR"},{"label":"Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV","type":"EXPERIMENTAL"},{"label":"Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC","type":"EXPERIMENTAL"},{"label":"Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC","type":"EXPERIMENTAL"},{"label":"Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV","type":"EXPERIMENTAL"},{"label":"Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo","type":"EXPERIMENTAL"}],"summary":"The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2.\n\nThe objective of Sub-Study 2 is to evaluate the efficacy and safety of risankizumab compared to placebo in inducing clinical remission in subjects with moderately to severely active UC.","primaryOutcome":{"measure":"Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score","timeFrame":"Week 12","effectByArm":[{"arm":"Substudy 1, Induction Period 1: Double-blind Placebo IV","deltaMin":1,"sd":null},{"arm":"Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV","deltaMin":7,"sd":null},{"arm":"Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV","deltaMin":6,"sd":null},{"arm":"Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV","deltaMin":6,"sd":null},{"arm":"Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV","deltaMin":42,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0324"},{"comp":"OG000 vs OG002","p":"0.0460"},{"comp":"OG000 vs OG003","p":"0.0397"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":430,"countries":["United States","Argentina","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Denmark","Egypt","France","Germany","Greece","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","Poland","Portugal","Puerto Rico","Romania","Russia","Serbia","Singapore","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["40168091","39804294","39037800"],"seeAlso":["https://www.abbvieclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":59},"commonTop":["NASOPHARYNGITIS","HEADACHE","ANAEMIA","COVID-19","COLITIS ULCERATIVE"]}}